Centrus Energy (NYSE: LEU) is emerging as one of the most strategically important yet overlooked players in the global nuclear energy resurgence currently underway.
While investors have rushed toward small modular reactor startups Oklo (NYSE: OKLO) and NuScale for nuclear exposure, neither company can operate a single reactor without a critical ingredient: specialized nuclear fuel.
Centrus Energy sits at the center of that supply chain, producing the enriched uranium that next-generation nuclear reactors require to function at all.
The company pioneered the production of High-Assay, Low-Enriched Uranium, known as HALEU, which is required for most U.S. advanced reactor designs, particularly the smaller modular configurations attracting heavy investment.
Centrus operates a facility in Piketon, Ohio, which became the first site in the country to receive a license from the U.S. Nuclear Regulatory Commission to produce HALEU commercially.
That regulatory milestone gives Centrus a significant first-mover advantage in a market where fuel supply is fast becoming as competitive a concern as reactor design itself.
Oklo signed a letter of intent earlier this year to purchase fuel from Centrus for its Aurora Powerhouse Deployment in Ohio, a planned 1.2 gigawatt clean energy campus intended to supply power to Meta Platforms to support its regional data centers.
Centrus and Oklo have since deepened that relationship, agreeing to pursue a joint venture focused on HALEU deconversion services and advancing related fuel-cycle technologies and supply chains.
Beyond Oklo, Centrus has secured a multi-year HALEU contract with Antares Nuclear, a long-term HALEU supply partnership with Radiant, and a HALEU supply deal with X-energy, underscoring the breadth of demand across the sector.
Unlike the SMR startups drawing much of the market’s attention, Centrus is already generating meaningful and growing revenue from its operations today.
The company reported $176.1 million in revenue during the second quarter, representing a 14% increase compared to the same period the previous year.
That financial performance stands in stark contrast to Oklo and NuScale, neither of which currently generates commercial power or substantial revenue from reactor operations.
For investors seeking real nuclear exposure backed by actual earnings rather than speculative timelines, Centrus offers a fundamentally different risk profile than the SMR startups dominating headlines.
As the global push toward clean energy accelerates and advanced reactor deployments move closer to reality, demand for HALEU is expected to rise sharply, positioning Centrus at a critical chokepoint in the nuclear supply chain.
